4,699 件 ・ 関連度順
概要と使いどころ
Find deepening opportunities in a codebase, informed by the project's own domain language and prior design decisions. Use when the user wants to improve architecture, find refactoring opportunities, consolidate tightly-coupled modules, or make a codebase more testable and AI-navigable.
日本語の概要は準備中です。原文の説明を表示しています。
Build UpSet plots to visualize set intersections beyond 4 sets (where Venn fails) using ComplexUpset (modern, ggplot2-grammar) or the unmaintained UpSetR, with explicit cardinality vs degree sorting, attribute panels, and query highlighting. Use when comparing overlap across many gene sets, peak sets, variant lists, or any set membership matrix where Venn diagrams become illegible.
日本語の概要は準備中です。原文の説明を表示しています。
Cross-method decision tree for calling hits in pooled CRISPR screens. Catalogs statistical models (MAGeCK RRA, MAGeCK MLE, BAGEL2, drugZ, JACKS, Chronos, CERES), experimental designs each is built for, failure modes outside design domain, reconciliation when methods disagree, multiple-testing and effect-size thresholds, the order of operations (count -> QC -> CN-correct -> hit-call -> validate), the second-best-sgRNA conservative rule, and consensus-hit strategy. Use when choosing among MAGeCK / BAGEL2 / drugZ / JACKS / Chronos for a given design, reconciling disagreement across two or three methods on the same screen, deciding whether to require consensus, gating downstream validation by hit-confidence tier, or interpreting unstable hit lists across reruns.
日本語の概要は準備中です。原文の説明を表示しています。
Reads, validates, and prepares CDISC SDTM and ADaM clinical trial data for analysis. Covers SDTM domain joins (DM, AE, EX, VS, LB, DS), ADaM architecture (ADSL, BDS, OCCDS, ADTTE) with traceability, treatment-emergent AE conventions, baseline derivation, SUPPQUAL/NSV handling, Define-XML 2.1, and Pinnacle 21 / CORE validation. Use when working with clinical trial datasets in CDISC SDTM/ADaM format, preparing analysis-ready data, or validating for regulatory submission.
日本語の概要は準備中です。原文の説明を表示しています。
Identifies super-enhancers from H3K27ac, MED1, or BRD4 ChIP-seq using ROSE, ROSE2, LILY, HOMER -style super, and ENCODE dELS cross-referencing. Handles peak stitching parameters, ranking choices, hockey-stick inflection, marker choice (H3K27ac vs MED1/BRD4), and cross-condition comparison with spike-in normalization. Constructs core regulatory circuitry (Saint-Andre 2016) from SE-encoded TFs. Use when identifying cell-identity / cancer-associated regulatory domains, comparing super-enhancers between conditions, identifying master transcription factor networks, or predicting BET-inhibitor responsiveness.
日本語の概要は準備中です。原文の説明を表示しています。
Track complex, multi-session work with dependency graphs using bd (beads) issue tracker. Use when work spans multiple sessions, has complex dependencies, or requires persistent context across compaction cycles. For simple single-session linear tasks, TodoWrite remains appropriate.
日本語の概要は準備中です。原文の説明を表示しています。
Predicts ADMET properties using ADMETlab 3.0 (119 platform features, including 77 prediction models with modeled-endpoint uncertainty), ADMET-AI, DeepChem MolNet, and chemprop D-MPNN with explicit handling of OECD QSAR principles, applicability domain assessment, calibration, hERG/CYP/AMES endpoints, and PAINS / Lipinski / Ro5 / Veber / BBB druglikeness filters. Use when filtering compounds for drug-likeness, prioritizing leads by predicted safety, or building an in-house ADMET QSAR model.
日本語の概要は準備中です。原文の説明を表示しています。
Master REST and GraphQL API design principles to build intuitive, scalable, and maintainable APIs that delight developers. Use when designing new APIs, reviewing API specifications, or establishing API design standards.
日本語の概要は準備中です。原文の説明を表示しています。
Assess whether a hospitalized adult with diabetes on insulin pump therapy remains a candidate for continued inpatient pump use. Consider triggers such as the clinician asking "Is this patient appropriate to continue insulin pump in hospital?" and evaluate for impaired consciousness, inability to adjust pump settings, critical illness, DKA, or hyperosmolar hyperglycemic state.
日本語の概要は準備中です。原文の説明を表示しています。
This skill suggests continuing personal CGM with or without ADIP rather than discontinuation for inpatients already using it who are at high risk for hypoglycemia. Trigger phrases include "Should I continue or discontinue personal CGM for this inpatient who is already using it?" and "Is it appropriate to maintain personal CGM during hospitalization?"
日本語の概要は準備中です。原文の説明を表示しています。
Recommends continuing a patient’s personal continuous glucose monitor (CGM) in the hospital with or without algorithm-driven insulin pump (ADIP) therapy rather than discontinuing it for individuals already using CGM outpatient. Use when deciding whether to maintain personal CGM during admission or when a patient requests to keep their device, particularly in those at high risk for hypoglycemia.
日本語の概要は準備中です。原文の説明を表示しています。
Suggests that adults with type 1 or type 2 diabetes using continuous subcutaneous insulin infusion (CSII) and continuous glucose monitoring (CGM) receive education, training, and ongoing support to achieve and maintain individualized glycemic goals. Trigger phrases include: 'Patient on pump plus CGM, arrange education' and 'Ensure CSII+CGM users get training and support'.
日本語の概要は準備中です。原文の説明を表示しています。
This skill confirms that medical therapy has normalized cortisol before initiating radiation therapy or radiosurgery for Cushing's syndrome to maintain disease control while awaiting radiation effect. It is triggered when planning pituitary RT/radiosurgery for a patient with persistent or recurrent Cushing's disease after transsphenoidal surgery (TSS) or when medical therapy is being used as a bridge to radiation.
日本語の概要は準備中です。原文の説明を表示しています。
This skill suggests radiation therapy or radiosurgery for adult patients with Cushing's disease who have failed transsphenoidal surgery (TSS) or have recurrent disease after initial remission. Consider when postoperative urinary free cortisol or late-night salivary cortisol remains elevated, or when clinical recurrence is suspected.
日本語の概要は準備中です。原文の説明を表示しています。
Recommends adding intravenous bisphosphonate or denosumab in adults with hypercalcemia of malignancy due to tumors with high calcitriol levels (e.g., lymphoma) who remain severe or symptomatic despite glucocorticoid therapy. Use when managing lymphoma‑related HCM on steroids and considering escalation of antiresorptive therapy.
日本語の概要は準備中です。原文の説明を表示しています。
Recommends withdrawing interfering medications and repeating aldosterone-to-renin ratio screening when initial screen is negative but clinical suspicion remains due to hypokalemia or medication interference. Trigger phrases include "initial screen negative", "hypokalemia", "resistant hypertension", and use of MRAs, ACE inhibitors, ARBs, beta-blockers, clonidine, or alpha-methyldopa.
日本語の概要は準備中です。原文の説明を表示しています。
In patients with primary aldosteronism receiving mineralocorticoid receptor antagonist therapy, the guideline recommends titrating the MRA dose upward to raise renin when blood pressure remains uncontrolled and renin is suppressed. Consider this step when hypertension is not at goal despite MRA therapy and plasma renin activity (or direct renin concentration) is low.
日本語の概要は準備中です。原文の説明を表示しています。
Reconcile baseline-versioned files that the `create-baseline upgrade` CLI staged for LLM-assisted semantic merge. Use when the CLI prints "Open Claude Code and run /upgrade-project to reconcile". Reads the stage manifest at `.claude/state/upgrade/<ts>/manifest.json`, reasons through each pending file's three-way delta in main context, writes a reconciled LOCAL, then deletes the stage when every file lands. Supports `--dry-run` (preview the reconciled diff without writing) and a structured "needs-user-input" fallback when the conflict cannot be disambiguated automatically.
日本語の概要は準備中です。原文の説明を表示しています。
Workflow Phase 6 — TDD coordinator. Decides the scenario recipe and the implementation contract in main context, writes them to a state file, seeds per-worker tasks (scenario, implement, verify-tick, design-ui-tick) into the TaskList, and yields with harness_state continue so the harness invokes each worker as its own tick. No subagent delegation; no nested Skill calls.
日本語の概要は準備中です。原文の説明を表示しています。
On-demand "what's new" generator. Main context (which knows the impending change) writes keepachangelog-style entries to a fragment file at `.claude/state/whatsnew/<slug>.json` (gitignored, transient). An optional per-project `project.json → whatsnew.route_workflow` names a routing workflow that consumes the fragment and renders it wherever the project wants (a site page, a release body, a docs page). Not a workflow phase — it never blocks a commit, and it never writes `CHANGELOG.md` (that file is owned solely by semantic-release in CI).
日本語の概要は準備中です。原文の説明を表示しています。
Workflow Phase 3 — Research and Solution Exploration. Surfaces 2–4 candidate solution approaches with concrete tradeoffs, grounded in current library docs (fetched through the provider named in `.claude/docs-provider.json`) — never in training-data recall. Output lives at `docs/research/<slug>.md`. Candidate ranking and the memo execute in main context; doc/source gathering MAY be delegated to read-only advisory subagents (seed.md §4.2-A).
日本語の概要は準備中です。原文の説明を表示しています。
Dev-only review of user-facing CLI interface copy in `src/cli/tui/*.js`, `src/cli/*.js` error paths, and `bin/cli.js` help/usage text. Surfaces three failure modes — copy/behavior mismatch, jargon, missing next-action — as a punch list the maintainer addresses before `/grant-commit`. Read-only; no writes to source. Conditionally seeded by `/triage` between `/memory-sync` and `/grant-commit` when the request will touch CLI surfaces.
日本語の概要は準備中です。原文の説明を表示しています。
Write executable failing tests from a recipe handed to you by the main context. Used by `/tdd` Step 2 and ad-hoc when a phase needs tests-first to drive implementation. Decisions about which scenarios to cover, which categories matter, and which fixtures to use are made by the caller — this skill executes that recipe with code-structure discipline.
日本語の概要は準備中です。原文の説明を表示しています。
Run an org-team workflow — a flat pod of up to four peer Claude Code sessions claims lane-tagged slices of an approved spec over the baseline MCP channel and implements them concurrently, each in its own git worktree. Each peer DECIDES its own in-lane implementation choices in its own main context (Article X); only un-decidable or cross-lane forks escalate peer→lead→human (yield_fork for task-bound forks, ask_lead for free-form queries). Opt-in and OFF by default (velocity.org_mode.enabled). Graduates the retired sprint-dispatch prototype into the constitutionally-sanctioned org-team model (Article X — Multi-session coordinated workflows). Requires git.
日本語の概要は準備中です。原文の説明を表示しています。